Pharmacogenomics and pharmacotranscriptomics of glucocorticoids in pediatric acute lymphoblastic leukemia
Аутори
Gašić, VladimirPavlović, Đorđe
Stanković, Biljana
Kotur, Nikola
Zukić, Branka
Pavlović, Sonja
Остала ауторства
Celso, PereiraПоглавље у монографији (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Pharmacogenomics and pharmacotranscriptomics contribute to more efficient and safer treatment of many diseases, especially malignancies. Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy during childhood. Glucocorticoids, prednisone and dexamethasone, represent the basis of chemotherapy in pediatric ALL. Therapy causes side effects in 75% of patients and 1–3% of pediatric ALL patients die because of therapy side effects rather than the disease itself. Due to this fact, pharmacogenomics and pharmacotranscriptomics have gained key positions in this field. There is a growing knowledge of pharmacogenomics and pharmacotranscriptomics markers relevant for the success of the glucocorticoid treatment of children with ALL. New technologies, such as next-generation sequencing (NGS) have created a possibility for designing panels of pharmacogenomics and pharmacotranscriptomics markers related to the response to glucocorticoid drugs. Optimization of these panels throug...h population pharmacogenomic studies leads to new knowledge that could open the doors widely to pre-emptive pharmacogenomic testing.
Извор:
Corticosteroids : A Paradigmatic Drug Class, 2021, 1-17Издавач:
- IntechOpen
Финансирање / пројекти:
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200042 (Универзитет у Београду, Институт за молекуларну генетику и генетичко инжењерство) (RS-MESTD-inst-2020-200042)
Институција/група
Institut za molekularnu genetiku i genetičko inženjerstvoTY - CHAP AU - Gašić, Vladimir AU - Pavlović, Đorđe AU - Stanković, Biljana AU - Kotur, Nikola AU - Zukić, Branka AU - Pavlović, Sonja PY - 2021 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/1620 AB - Pharmacogenomics and pharmacotranscriptomics contribute to more efficient and safer treatment of many diseases, especially malignancies. Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy during childhood. Glucocorticoids, prednisone and dexamethasone, represent the basis of chemotherapy in pediatric ALL. Therapy causes side effects in 75% of patients and 1–3% of pediatric ALL patients die because of therapy side effects rather than the disease itself. Due to this fact, pharmacogenomics and pharmacotranscriptomics have gained key positions in this field. There is a growing knowledge of pharmacogenomics and pharmacotranscriptomics markers relevant for the success of the glucocorticoid treatment of children with ALL. New technologies, such as next-generation sequencing (NGS) have created a possibility for designing panels of pharmacogenomics and pharmacotranscriptomics markers related to the response to glucocorticoid drugs. Optimization of these panels through population pharmacogenomic studies leads to new knowledge that could open the doors widely to pre-emptive pharmacogenomic testing. PB - IntechOpen T2 - Corticosteroids : A Paradigmatic Drug Class T2 - glucocorticoids T2 - pediatric acute lymphoblastic leukemia T2 - pharmacogenomics T2 - pharmacotranscriptomics T2 - population pharmacogenomics T1 - Pharmacogenomics and pharmacotranscriptomics of glucocorticoids in pediatric acute lymphoblastic leukemia EP - 17 SP - 1 DO - 10.5772/intechopen.98887 ER -
@inbook{ author = "Gašić, Vladimir and Pavlović, Đorđe and Stanković, Biljana and Kotur, Nikola and Zukić, Branka and Pavlović, Sonja", year = "2021", abstract = "Pharmacogenomics and pharmacotranscriptomics contribute to more efficient and safer treatment of many diseases, especially malignancies. Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy during childhood. Glucocorticoids, prednisone and dexamethasone, represent the basis of chemotherapy in pediatric ALL. Therapy causes side effects in 75% of patients and 1–3% of pediatric ALL patients die because of therapy side effects rather than the disease itself. Due to this fact, pharmacogenomics and pharmacotranscriptomics have gained key positions in this field. There is a growing knowledge of pharmacogenomics and pharmacotranscriptomics markers relevant for the success of the glucocorticoid treatment of children with ALL. New technologies, such as next-generation sequencing (NGS) have created a possibility for designing panels of pharmacogenomics and pharmacotranscriptomics markers related to the response to glucocorticoid drugs. Optimization of these panels through population pharmacogenomic studies leads to new knowledge that could open the doors widely to pre-emptive pharmacogenomic testing.", publisher = "IntechOpen", journal = "Corticosteroids : A Paradigmatic Drug Class, glucocorticoids, pediatric acute lymphoblastic leukemia, pharmacogenomics, pharmacotranscriptomics, population pharmacogenomics", booktitle = "Pharmacogenomics and pharmacotranscriptomics of glucocorticoids in pediatric acute lymphoblastic leukemia", pages = "17-1", doi = "10.5772/intechopen.98887" }
Gašić, V., Pavlović, Đ., Stanković, B., Kotur, N., Zukić, B.,& Pavlović, S.. (2021). Pharmacogenomics and pharmacotranscriptomics of glucocorticoids in pediatric acute lymphoblastic leukemia. in Corticosteroids : A Paradigmatic Drug Class IntechOpen., 1-17. https://doi.org/10.5772/intechopen.98887
Gašić V, Pavlović Đ, Stanković B, Kotur N, Zukić B, Pavlović S. Pharmacogenomics and pharmacotranscriptomics of glucocorticoids in pediatric acute lymphoblastic leukemia. in Corticosteroids : A Paradigmatic Drug Class. 2021;:1-17. doi:10.5772/intechopen.98887 .
Gašić, Vladimir, Pavlović, Đorđe, Stanković, Biljana, Kotur, Nikola, Zukić, Branka, Pavlović, Sonja, "Pharmacogenomics and pharmacotranscriptomics of glucocorticoids in pediatric acute lymphoblastic leukemia" in Corticosteroids : A Paradigmatic Drug Class (2021):1-17, https://doi.org/10.5772/intechopen.98887 . .